Search results
Showing 46 to 59 of 59 results for durvalumab
Awaiting development Reference number: GID-TA11828 Expected publication date: TBC
Awaiting development Reference number: GID-TA11671 Expected publication date: TBC
Awaiting development Reference number: GID-TA11835 Expected publication date: TBC
Awaiting development Reference number: GID-TA10967 Expected publication date: TBC
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.
Discontinued Reference number: GID-TA11289
Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
In development Reference number: GID-TA11569 Expected publication date: TBC
In development Reference number: GID-TA11624 Expected publication date: TBC
Discontinued Reference number: GID-TA10783
This guidance has been updated and replaced by NICE technology appraisal guidance TA798.
Technology appraisal and highly specialised technologies appeals
Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.
Hundreds of people set to benefit after life-extending lung cancer treatment given green light
Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung cancer has been recommended by NICE.
More than 400 people could benefit from life-extending advanced lung cancer treatment
Durvalumab recommended as an option for treating non-small-cell lung cancer.